BillionToOne ctDNA Test Matches Tumor-Informed Rival in Study
A peer-reviewed study found BillionToOne's tissue-free Northstar Response achieved 94% concordance with tumor-informed ctDNA testing for cancer monitoring.
A new peer-reviewed study shows that BillionToOne's tissue-free liquid biopsy test, Northstar Response, performs on par with or better than tumor-informed circulating tumor DNA assays in monitoring cancer treatment response, according to findings published Tuesday.
The head-to-head comparison recorded 94% concordance between the two testing approaches. Notably, in every case where the two methods produced conflicting results, the clinical ground truth — the real-world patient outcome data used as the benchmark — sided with the tissue-free Northstar Response test rather than the tumor-informed assay.
Read more NJ Liquor License Reform Explored in New Podcast Episode →
The distinction between the two technologies carries practical weight for oncology care. Tumor-informed ctDNA tests require a tissue biopsy sample to first map a patient's tumor mutations, adding time, cost, and procedural burden. Tissue-free assays like Northstar Response eliminate that step, potentially broadening access and accelerating clinical decision-making for patients undergoing cancer treatment.
The findings, if replicated across larger cohorts and cancer types, could support a case for tissue-free liquid biopsy as a primary monitoring tool rather than a secondary option. Analysts following the liquid biopsy sector have noted growing competition among developers to validate assays without the tumor-sequencing prerequisite, which has historically been seen as a differentiating quality benchmark for accuracy.
BillionToOne did not disclose the specific cancer types, patient sample size, or journal in the announcement summary reviewed. Continue reading at GlobeNewswire - Industry News on Financial Services.
